Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers

Molecular Therapy - Oncolytics

Volumn 3, Issue , 2016, Pages 15021-

  Nguyen, Tien V ^a   Heller, Greg J ^b   Barry, Mary E ^a   Crosby, Catherine M ^c   Turner, Mallory A ^c   Barry, Michael A ^a,d,e  

^a Program in Translational Immunovirology and Biodefense   (United States)

^b Postbaccalaureate Research Education Program   (United States)

^c Virology and Gene Therapy Graduate Program   (United States)

^d Department of Immunology ^*  (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS SEROTYPE 6; ALANINE AMINOTRANSFERASE; INTERLEUKIN 6; MACROGOL; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LIVER INJURY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TUMOR VOLUME;

EID: 84969277547     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2015.21     Document Type: Article

References (54)

1. Post, DE, Khuri, FR, Simons, JW and Van Meir, EG (2003).Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14: 933-946.
2. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
3. Prestwich, RJ, Errington, F, Diaz, RM, Pandha, HS, Harrington, KJ, Melcher, AA et al. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.
4. Davison, AJ, Benko, M and Harrach, B (2003). Genetic content and evolution of adenoviruses. J Gen Virol 84(Pt 11): 2895-2908.
5. Pereira, HG and Kelly, B (1957). Dose-response curves of toxic and infective actions of adenovirus in HeLa cell cultures. J Gen Microbiol 17: 517-524.
6. Huebner, RJ, Rowe, WP, Schatten, WE, Smith, RR and Thomas, LB (1956). Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211-1218.
7. Schenk, E, Essand, M, Kraaij, R, Adamson, R, Maitland, NJ and Bangma, CH (2014). Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Hum Gene Ther Clin Dev 25: 7-15.
8. Dong, W, van Ginkel, JW, Au, KY, Alemany, R, Meulenberg, JJ and van Beusechem, VW (2014). ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. Hum Gene Ther 25: 897-904.
9. Xu, W, Neill, T, Yang, Y, Hu, Z, Cleveland, E, Wu, Y et al. (2015). The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther 22: 247-256.
10. Taneja, SS (2015). Re: Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. J Urol 193: 847.
11. Mao, LJ, Zhang, J, Liu, N, Fan, L, Yang, DR, Xue, BX et al. (2015). Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis. Tumour Biol 36: 9073-9081.
12. Liu, Y, Chen, L, Gong, Z, Shen, L, Kao, C, Hock, JM et al. (2015). Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Oncotarget 6: 3055-3070.
13. Gibson, H, Munns, S, Freytag, S, Barton, K, Veenstra, J, Bettahi, I et al. (2015). Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncoimmunology 4: e984523.
14. Piedra, PA, Poveda, GA, Ramsey, B, McCoy, K and Hiatt, PW (1998). Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101: 1013-1019.
15. Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
16. Hemminki, A, Kanerva, A, Kremer, EJ, Bauerschmitz, GJ, Smith, BF, Liu, B et al. (2003). A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 7: 163-173.
17. Hoffmann, D, Bayer, W, Heim, A, Potthoff, A, Nettelbeck, DM and Wildner, O (2008). Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J Invest Dermatol 128: 988-998.
18. Hoffmann, D, Heim, A, Nettelbeck, DM, Steinstraesser, L and Wildner, O (2007). Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum Gene Ther 18: 51-62.
19. Strauss, R, Sova, P, Liu, Y, Li, ZY, Tuve, S, Pritchard, D et al. (2009). Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res 69: 5115-5125.
20. Shashkova, EV, May, SM and Barry, MA (2009). Characterization of human adenovirus serotypes 5, 6, 11, 35 as anticancer agents. Virology 394: 311-320.
21. Senac, JS, Doronin, K, Russell, SJ, Jelinek, DF, Greipp, PR and Barry, MA (2010). Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 21: 179-190.
22. Chen, CY, Senac, JS, Weaver, EA, May, SM, Jelinek, DF, Greipp, P et al. (2011). Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res 17: 6712-6722.
23. Chen, CY, Weaver, EA, Khare, R, May, SM and Barry, MA (2011). Mining the adenovirus virome for oncolytics against multiple solid tumor types. Cancer Gene Ther 18: 744-750.
24. Weaver, EA, Hillestad, ML, Khare, R, Palmer, D, Ng, P and Barry, MA (2011). Characterization of species C human adenovirus serotype 6 (Ad6). Virology 412: 19-27.
25. Blusch, JH, Deryckere, F, Windheim, M, Ruzsics, Z, Arnberg, N, Adrian, T et al. (2002). The novel early region 3 protein E3/49K is specifically expressed by adenoviruses of subgenus D: implications for epidemic keratoconjunctivitis and adenovirus evolution. Virology 296: 94-106.
26. Khare, R, May, SM, Vetrini, F, Weaver, EA, Palmer, D, Rosewell, A et al. (2011). Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther 19: 1254-1262.
27. Khare, R, Hillestad, ML, Xu, Z, Byrnes, AP and Barry, MA (2013). Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol 87: 3678-3686.
28. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, complement. J Virol 82: 11705-11713.
29. Barry, MA, Hofherr, SE, Chen, CY, Senac, JS, Hillestad, ML and Shashkova, EV (2009). Systemic delivery of therapeutic viruses. Curr Opin Mol Ther 11: 411-420.
30. Khare, R, Chen, CY, Weaver, EA and Barry, MA (2011). Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11: 241-258.
31. Doronin, K, Shashkova, EV, May, SM, Hofherr, SE and Barry, MA (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 20: 975-988.
32. O'Riordan, CR, Lachapelle, A, Delgado, C, Parkes, V, Wadsworth, SC, Smith, AE et al. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10: 1349-1358.
33. Croyle, MA, Chirmule, N, Zhang, Y and Wilson, JM (2001). "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75: 4792-4801.
34. Croyle, MA, Chirmule, N, Zhang, Y and Wilson, JM (2002). PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13: 1887-1900.
35. Mok, H, Palmer, DJ, Ng, P and Barry, MA (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79.
36. Croyle, MA, Le, HT, Linse, KD, Cerullo, V, Toietta, G, Beaudet, A et al. (2005). PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 12: 579-587.
37. Hofherr, SE, Mok, H, Gushiken, FC, Lopez, JA and Barry, MA (2007). Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, thrombocytopenia. Hum Gene Ther 18: 837-848.
38. Stone, KR, Mickey, DD, Wunderli, H, Mickey, GH and Paulson, DF (1978). Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281.
39. Horoszewicz, JS, Leong, SS, Kawinski, E, Karr, JP, Rosenthal, H, Chu, TM et al. (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818.
40. Sumida, SM, Truitt, DM, Lemckert, AA, Vogels, R, Custers, JH, Addo, MM et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
41. Vogels, R, Zuijdgeest, D, van Rijnsoever, R, Hartkoorn, E, Damen, I, de Bethune, MP et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271.
42. Shashkova, EV, Spencer, JF, Wold, WS and Doronin, K (2007). Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spreadenhanced oncolytic adenovirus. Mol Ther 15: 598-607.
43. Yang, Y, Ertl, HC and Wilson, JM (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1: 433-442.
44. Horwitz, MS (2004). Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med 6 Suppl 1: S172-S183.
45. Lichtenstein, DL, Toth, K, Doronin, K, Tollefson, AE and Wold, WS (2004). Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 23: 75-111.
46. Suzuki, K, Alemany, R, Yamamoto, M and Curiel, DT (2002). The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 8: 3348-3359.
47. Wang, Y, Hallden, G, Hill, R, Anand, A, Liu, TC, Francis, J et al. (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335.
48. Campos, SK and Barry, MA (2004). Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther 15: 1125-1130.
49. Weaver, EA, Palmer, D, Ng, P and Barry, MA (2011). Characterization of species C human adenovirus serotype 6 (Ad6). Virology 412: 19-27.
50. Shashkova, EV, May, SM, Doronin, K and Barry, MA (2009). Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther 17: 2121-2130.
51. Shayakhmetov, DM, Gaggar, A, Ni, S, Li, ZY and Lieber, A (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491.
52. Parker, AL, Waddington, SN, Nicol, CG, Shayakhmetov, DM, Buckley, SM, Denby, L et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirusmediated gene delivery to hepatocytes. Blood 108: 2554-2561.
53. Hofherr, SE, Shashkova, EV, Weaver, EA, Khare, R and Barry, MA (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 16: 1276-1282.
54. Weaver, EA and Barry, MA (2013). Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS One 8: e73313.